Welcome to our dedicated page for GWII news (Ticker: GWII), a resource for investors and traders seeking the latest updates and insights on GWII stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GWII's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GWII's position in the market.
Good Works II Acquisition Corp. (GWII) has signed an agreement to merge with Direct Biologics, a biotechnology company. This transaction will lead to Direct Biologics becoming publicly traded under the name Direct Biologics, Inc. in the first half of 2023. The deal includes a minimum cash condition of $75 million and a private placement of up to $100 million. Direct Biologics is developing ExoFlo™, currently in Phase 3 clinical trials for treating ARDS in COVID-19 patients, which has received FDA's RMAT designation.
Good Works II Acquisition Corp. (GWII) announced a non-binding letter of intent for a business combination with Direct Biologics, valuing the latter at $675 million. The deal aims to merge the two companies, creating a publicly traded entity focused on Direct Biologics' ExoFlo™, which is in Phase 3 trials for treating ARDS related to COVID-19. The transaction requires a minimum net cash of $75 million at closing, with plans to fund clinical trials and operational costs. A shareholder vote is scheduled for October 11, 2022, to extend the transaction deadline.
FAQ
What is the market cap of GWII (GWII)?
